Clinical Trial Update: A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating pembrolizumab with chemotherapy as neoadjuvant therapy for triple-negative breast cancer is ongoing with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN